Drilldown: Medicines
Medicines > classes 
:
Anti-amyloid beta (Aβ) monoclonal antibody or
Sedative-Hypnotic or
dissociative
:
Anti-amyloid beta (Aβ) monoclonal antibody or
Sedative-Hypnotic or
dissociative Use the filters below to narrow your results.
generic:
brand:
None (26) ·
(none, never marketed) (1) ·
Aduhelm (1) ·
Dalmane (1) ·
Doral (1) ·
Doriden (1) ·
DXM (1) ·
DXO (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Kisunla (1) ·
Leqembi (1) ·
Lunesta (1) ·
Mogadon (1) ·
Nembutal (1) ·
Placidyl (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Sonata (1) ·
Spravato (1) ·
THIP (1) ·
Versed (1) ·
Xyrem (1)
classes: (Click arrow to add another value)
mechanism:
None (5) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Contains salvinorin A (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
Melatonin receptor agonist (2) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1)
uses:
None (48) ·
Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) ·
Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) ·
Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
None (48) ·
10 mg/kg IV every 2 weeks (1) ·
700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) ·
Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)
preparations:
None (48) ·
200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) ·
28 mg/device (each dose uses 2 devices) (1) ·
350 mg/20 mL vial for IV infusion (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) ·
Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)
fda max:
routes:
onset:
None (48) ·
Amyloid PET clearance within months; cognitive benefit over 18 months (1) ·
PET Aβ reduction over months (1) ·
Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1) ·
Within hours of first administration (1) ·
~20–40 min PO; faster sublingual/intranasal. (1)
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 53 results in range #1 to #53.